Aspen Alert’s Post

In the latest edition of the "Welcome to the Future" series, Marcos Cortes, Managing Director of A&M’s Corporate Transactions Group, examines the implications of the Inflation Reduction Act (IRA) on pharmaceutical research and development. As the industry allocates a substantial share of revenue to R&D, adjustments in drug pricing are likely to affect upcoming R&D budgets and strategies. Check out Marcos's insights on Medicare drug negotiation under the IRA and its potential effects on the pharmaceutical sector and future innovation investments. https://okt.to/KSaqVF #InflationReductionAct #CorporateTransactionsGroup

AstraZeneca acknowedges that the #InflationReducationAct is not a threat to their business. Two recent papers from the Center for Integration of Science and Industry at Bentley University expain why. https://lnkd.in/e9FkHXcU https://lnkd.in/epvzMPH9 "...president of AstraZeneca’s biopharma business unit, in a media call said that the company has finished Medicare drug price negotiations for its diabetes drug #Farxiga (dapagliflozin). Overall, the impact of the Inflation Reduction Act on Farxiga “will be very limited,...” The company also noted that "....we set out a new revenue ambition to deliver $80 billion of Total Revenue by 2030. This is a clear reflection of the substantial growth potential we see from both our approved medicines and those in our late-stage pipeline." #innovation #finance #research #development #revenue #profit #drugdevelopment, #drugdiscovery Bentley University Center for Health and Business #InflationReductionAct Institute for New Economic Thinking West Health Policy Center

Bristol Myers Squibb’s Q3 2024 earnings highlight both opportunities and challenges in the ever-evolving pharmaceutical landscape. The company's reported financials and growth strategies underline its commitment to innovation while navigating market pressures. As we move forward, it’s fascinating to see how strategic investments and a focus on transformative therapies will shape the industry. This serves as a reminder of the critical role life sciences play in improving global health and well-being. Excited to see how Bristol Myers Squibb continues to lead in driving breakthroughs for patients worldwide! #PharmaceuticalInnovation #LifeSciences #HealthcareLeadership #BusinessInsights

Q2 #biopharma earnings season is in full swing and the #InflationReductionAct’s #Medicare Drug Price Negotiation Program has been on the minds of #BigPharma execs, with #drugpricing talks between #CMS and companies ending next week. Despite their kicking and screaming, the #drugmakers seem confident negotiations will not greatly impact their bottom lines. https://lnkd.in/gGYX2dDQ #drugprices #pharma #pharmaceuticals

Strategic planning is the answer to evolving IRA questions for biopharma companies. In a recent Pharmaceutical Executive article, Corey Ford, VP of Reimbursement & Policy Insights, explains how companies can leverage tactics, such as digital channels, to communicate critical value information: https://ow.ly/jGgX50SgUuT

Big Pharma is showing resilience in the face of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. Despite initial resistance, major companies like Johnson & Johnson, AstraZeneca, and Novartis remain optimistic about their financial outlooks, even after the first round of drug price negotiations. With legal challenges against the program failing, these companies are confident that the impact on their bottom lines will be limited. The industry is adapting, but it’s clear that the IRA isn’t shaking their foundations. https://lnkd.in/gCUf8zh5

A carrier finally acting in the best interest of their consumers. We've been doing this on the self insured side for years. If there is no competition, there are no price pressures. This approach will gain momentum and put additional pressure on PBMs to find a way to either get the pharmaceutical companies to reduce R&D costs or for both entities to reduce profits. However, don't expect the PBMs to go down without a fight. They have some of the best lobbyists in the world. https://lnkd.in/eGMd33fh

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth. The pharmaceutical giant also raised its full-year revenue and adjusted earnings forecast. The results come as Bristol Myers moves to slash $1.5 billion in costs by 2025 and funnel that money into key drug brands and research and development programs. https://lnkd.in/gQrrCs5m

Expert Discusses the Impact of Medicare Drug Pricing Reforms on the Pharmaceutical Industry: Access to certain drugs may be limited through tighter formulary controls and utilization management by Medicare Part D plans dealing with higher costs #finance #pharmacy #lifesciences